Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Eloxx Pharmaceuticals Inc is a biotechnology business based in the US. Eloxx Pharmaceuticals shares (ELOX) are listed on the NASDAQ and all prices are listed in US Dollars. Eloxx Pharmaceuticals employs 25 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $0.52 |
|---|---|
| 52-week range | $0.37 - $4.98 |
| 50-day moving average | $0.74 |
| 200-day moving average | $1.46 |
| Wall St. target price | $3.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.04 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.52 from 2022-01-26
| 1 week (2022-01-19) | 0.39% |
|---|---|
| 1 month (2021-12-28) | -25.18% |
| 3 months (2021-10-28) | -62.86% |
| 6 months (2021-07-28) | -62.59% |
| 1 year (2021-01-28) | -85.43% |
|---|---|
| 2 years (2020-01-28) | -86.97% |
| 3 years (2019-01-28) | 10.6 |
| 5 years (2017-01-27) | 160.00% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -51.66% |
| Return on equity TTM | -252.78% |
| Profit margin | 0% |
| Book value | $0.38 |
| Market capitalisation | $38.8 million |
TTM: trailing 12 months
We're not expecting Eloxx Pharmaceuticals to pay a dividend over the next 12 months.
Eloxx Pharmaceuticals's shares were split on a 1:20 basis on 19 December 2017. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Eloxx Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Eloxx Pharmaceuticals shares which in turn could have impacted Eloxx Pharmaceuticals's share price.
Over the last 12 months, Eloxx Pharmaceuticals's shares have ranged in value from as little as $0.3741 up to $4.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eloxx Pharmaceuticals's is 2.1353. This would suggest that Eloxx Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Eloxx Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts. .
Five major factors contribute to the continued bull run of Bitcoin, ARK says, including growing adoption and long-term focus of investors.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
The crypto market wiped out $1.5 trillion in value in just three months.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.